Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 6/2010

Open Access 01-12-2010 | Original Article

Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype

Authors: Marlies J. Valstar, Hennie T. Bruggenwirth, Renske Olmer, Ron A. Wevers, Frans W. Verheijen, Ben J. Poorthuis, Dicky J. Halley, Frits A. Wijburg

Published in: Journal of Inherited Metabolic Disease | Issue 6/2010

Login to get access

Abstract

Mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo syndrome type B) is a lysosomal storage disorder caused by deficiency of the enzyme N-acetyl-α-D-glucosaminidase (NAGLU). Information on the natural course of MPS IIIB is scarce but much needed in view of emerging therapies. To improve knowledge on the natural course, data on all 52 MPS IIIB patients ever identified by enzymatic studies in the Netherlands were gathered. Clinical data on 44 patients could be retrieved. Only a small number (n = 9; 21%) presented with a classical MPS III phenotype; all other patients showed a much more attenuated course of the disease characterized by a significantly slower regression of intellectual and motor abilities. The majority of patients lived well into adulthood. First signs of the disease, usually mild developmental delay, were observed at a median age of 4 years. Subsequently, patients showed a slowing and eventually a stagnation of development. Patients with the attenuated phenotype had a stable intellectual disability for many years. Molecular analysis was performed in 24 index patients. The missense changes p.R643C, p.S612G, p.E634K, and p.L497V were exclusively found in patients with the attenuated phenotype. MPS IIIB comprises a remarkably wide spectrum of disease severity, and an unselected cohort including all Dutch patients showed a large proportion (79%) with an attenuated phenotype. MPS IIIB must be considered in patients with a developmental delay, even in the absence of a progressive decline in intellectual abilities. A key feature, necessitating metabolic studies, is the coexistence of behavioral problems.
Literature
go back to reference Beesley CE, Young EP, Vellodi A et al. (1998) Identification of 12 novel mutations in the alpha-N-acetylglucosaminidase gene in 14 patients with Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB). J Med Genet 35:910–914CrossRefPubMed Beesley CE, Young EP, Vellodi A et al. (1998) Identification of 12 novel mutations in the alpha-N-acetylglucosaminidase gene in 14 patients with Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB). J Med Genet 35:910–914CrossRefPubMed
go back to reference Beesley C, Moraitou M, Winchester B et al. (2004) Sanfilippo B syndrome: molecular defects in Greek patients. Clin Genet 65:143–149CrossRefPubMed Beesley C, Moraitou M, Winchester B et al. (2004) Sanfilippo B syndrome: molecular defects in Greek patients. Clin Genet 65:143–149CrossRefPubMed
go back to reference Beesley CE, Jackson M, Young EP et al. (2005) Molecular defects in Sanfilippo syndrome type B (mucopolysaccharidosis IIIB). J Inherit Metab Dis 28:759–767CrossRefPubMed Beesley CE, Jackson M, Young EP et al. (2005) Molecular defects in Sanfilippo syndrome type B (mucopolysaccharidosis IIIB). J Inherit Metab Dis 28:759–767CrossRefPubMed
go back to reference Berger-Plantinga EG, Vanneste JA, Groener JE et al. (2004) Adult-onset dementia and retinitis pigmentosa due to mucopolysaccharidosis III-C in two sisters. J Neurol 251:479–481CrossRefPubMed Berger-Plantinga EG, Vanneste JA, Groener JE et al. (2004) Adult-onset dementia and retinitis pigmentosa due to mucopolysaccharidosis III-C in two sisters. J Neurol 251:479–481CrossRefPubMed
go back to reference Bunge S, Knigge A, Steglich C et al. (1999) Mucopolysaccharidosis type IIIB (Sanfilippo B): identification of 18 novel alpha-N-acetylglucosaminidase gene mutations. J Med Genet 36:28–31PubMed Bunge S, Knigge A, Steglich C et al. (1999) Mucopolysaccharidosis type IIIB (Sanfilippo B): identification of 18 novel alpha-N-acetylglucosaminidase gene mutations. J Med Genet 36:28–31PubMed
go back to reference Champion KJ, Basehore MJ, Wood T et al. (2010) Identification and characterization of a novel homozygous deletion in the alpha-N-acetylglucosaminidase gene in a patient with Sanfilippo type B syndrome (mucopolysaccharidosis IIIB). Mol Genet Metab 100:51–56 Champion KJ, Basehore MJ, Wood T et al. (2010) Identification and characterization of a novel homozygous deletion in the alpha-N-acetylglucosaminidase gene in a patient with Sanfilippo type B syndrome (mucopolysaccharidosis IIIB). Mol Genet Metab 100:51–56
go back to reference Chinen Y, Tohma T, Izumikawa Y et al. (2005) Sanfilippo type B syndrome: five patients with an R565P homozygous mutation in the alpha-N-acetylglucosaminidase gene from the Okinawa islands in Japan. J Hum Genet 50:357–359CrossRefPubMed Chinen Y, Tohma T, Izumikawa Y et al. (2005) Sanfilippo type B syndrome: five patients with an R565P homozygous mutation in the alpha-N-acetylglucosaminidase gene from the Okinawa islands in Japan. J Hum Genet 50:357–359CrossRefPubMed
go back to reference Coll MJ, Anton C, Chabas A (2001) Allelic heterogeneity in Spanish patients with Sanfilippo disease type B. Identification of eight new mutations. J Inherit Metab Dis 24:83–84CrossRefPubMed Coll MJ, Anton C, Chabas A (2001) Allelic heterogeneity in Spanish patients with Sanfilippo disease type B. Identification of eight new mutations. J Inherit Metab Dis 24:83–84CrossRefPubMed
go back to reference Di Domenico C, Villani GR, Di Napoli D et al. (2009) Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB. Am J Med Genet A 149A:1209–1218CrossRefPubMed Di Domenico C, Villani GR, Di Napoli D et al. (2009) Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB. Am J Med Genet A 149A:1209–1218CrossRefPubMed
go back to reference Emre S, Terzioglu M, Tokatli A et al. (2002) Sanfilippo syndrome in Turkey: identification of novel mutations in subtypes A and B. Hum Mutat 19:184–185CrossRefPubMed Emre S, Terzioglu M, Tokatli A et al. (2002) Sanfilippo syndrome in Turkey: identification of novel mutations in subtypes A and B. Hum Mutat 19:184–185CrossRefPubMed
go back to reference Esposito S, Balzano N, Daniele A et al. (2000) Heparan N-sulfatase gene: two novel mutations and transient expression of 15 defects. Biochim Biophys Acta 1501:1–11PubMed Esposito S, Balzano N, Daniele A et al. (2000) Heparan N-sulfatase gene: two novel mutations and transient expression of 15 defects. Biochim Biophys Acta 1501:1–11PubMed
go back to reference Lee-Chen GJ, Lin SP, Lin SZ et al. (2002) Identification and characterisation of mutations underlying Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB). J Med Genet 39:E3CrossRefPubMed Lee-Chen GJ, Lin SP, Lin SZ et al. (2002) Identification and characterisation of mutations underlying Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB). J Med Genet 39:E3CrossRefPubMed
go back to reference Moog U, van Mierlo I, van Schrojenstein Lantman-de Valk HM et al. (2007) Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems? Am J Med Genet C Semin Med Genet 145C:293–301CrossRefPubMed Moog U, van Mierlo I, van Schrojenstein Lantman-de Valk HM et al. (2007) Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems? Am J Med Genet C Semin Med Genet 145C:293–301CrossRefPubMed
go back to reference Piotrowska E, Jakobkiewicz-Banecka J, Baranska S et al. (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14:846–852CrossRefPubMed Piotrowska E, Jakobkiewicz-Banecka J, Baranska S et al. (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14:846–852CrossRefPubMed
go back to reference Ponder KP, Haskins ME (2007) Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 7:1333–1345CrossRefPubMed Ponder KP, Haskins ME (2007) Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 7:1333–1345CrossRefPubMed
go back to reference Poorthuis BJ, Wevers RA, Kleijer WJ et al. (1999) The frequency of lysosomal storage diseases in the Netherlands. Hum Genet 105:151–156PubMed Poorthuis BJ, Wevers RA, Kleijer WJ et al. (1999) The frequency of lysosomal storage diseases in the Netherlands. Hum Genet 105:151–156PubMed
go back to reference Schmidtchen A, Greenberg D, Zhao HG et al. (1998) NAGLU mutations underlying Sanfilippo syndrome type B. Am J Hum Genet 62:64–69CrossRefPubMed Schmidtchen A, Greenberg D, Zhao HG et al. (1998) NAGLU mutations underlying Sanfilippo syndrome type B. Am J Hum Genet 62:64–69CrossRefPubMed
go back to reference Tessitore A, Villani GR, Di Natale DC et al. (2000) Molecular defects in the alpha-N-acetylglucosaminidase gene in Italian Sanfilippo type B patients. Hum Genet 107:568–576CrossRefPubMed Tessitore A, Villani GR, Di Natale DC et al. (2000) Molecular defects in the alpha-N-acetylglucosaminidase gene in Italian Sanfilippo type B patients. Hum Genet 107:568–576CrossRefPubMed
go back to reference Valstar MJ, Ruijter GJ, van Diggelen OP et al. (2008) Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 31:240–252CrossRef Valstar MJ, Ruijter GJ, van Diggelen OP et al. (2008) Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 31:240–252CrossRef
go back to reference Van de Kamp JJ, van Pelt JF, Liem KO et al. (1976) Clinical variability in Sanfilippo B disease: a report on six patients in two related sibships. Clin Genet 10:279–284CrossRefPubMed Van de Kamp JJ, van Pelt JF, Liem KO et al. (1976) Clinical variability in Sanfilippo B disease: a report on six patients in two related sibships. Clin Genet 10:279–284CrossRefPubMed
go back to reference Van de Kamp JJ, Niermeijer MF, von Figura FK et al. (1981) Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 20:152–160CrossRefPubMed Van de Kamp JJ, Niermeijer MF, von Figura FK et al. (1981) Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 20:152–160CrossRefPubMed
go back to reference Van Schrojenstein-de Valk HM, van de Kamp JJ (1987) Follow-up on seven adult patients with mild Sanfilippo B-disease. Am J Med Genet 28:125–129CrossRefPubMed Van Schrojenstein-de Valk HM, van de Kamp JJ (1987) Follow-up on seven adult patients with mild Sanfilippo B-disease. Am J Med Genet 28:125–129CrossRefPubMed
go back to reference Verhoeven WM, Csepan R, Marcelis CL et al. (2009) Sanfilippo B in an elderly female psychiatric patient: a rare but relevant diagnosis in presenile dementia. Acta Psychiatr Scand 122(2):162–165CrossRefPubMed Verhoeven WM, Csepan R, Marcelis CL et al. (2009) Sanfilippo B in an elderly female psychiatric patient: a rare but relevant diagnosis in presenile dementia. Acta Psychiatr Scand 122(2):162–165CrossRefPubMed
go back to reference Weber B, Blanch L, Clements PR et al. (1996) Cloning and expression of the gene involved in Sanfilippo B syndrome (mucopolysaccharidosis III B). Hum Mol Genet 5:771–777CrossRefPubMed Weber B, Blanch L, Clements PR et al. (1996) Cloning and expression of the gene involved in Sanfilippo B syndrome (mucopolysaccharidosis III B). Hum Mol Genet 5:771–777CrossRefPubMed
go back to reference Weber B, Guo XH, Kleijer WJ et al. (1999) Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. Eur J Hum Genet 7:34–44CrossRefPubMed Weber B, Guo XH, Kleijer WJ et al. (1999) Sanfilippo type B syndrome (mucopolysaccharidosis III B): allelic heterogeneity corresponds to the wide spectrum of clinical phenotypes. Eur J Hum Genet 7:34–44CrossRefPubMed
go back to reference Yogalingam G, Hopwood JJ (2001) Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: diagnostic, clinical, and biological implications. Hum Mutat 18:264–281CrossRefPubMed Yogalingam G, Hopwood JJ (2001) Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: diagnostic, clinical, and biological implications. Hum Mutat 18:264–281CrossRefPubMed
go back to reference Zhao HG, Li HH, Bach G et al. (1996) The molecular basis of Sanfilippo syndrome type B. Proc Natl Acad Sci USA 93:6101–6105CrossRefPubMed Zhao HG, Li HH, Bach G et al. (1996) The molecular basis of Sanfilippo syndrome type B. Proc Natl Acad Sci USA 93:6101–6105CrossRefPubMed
go back to reference Zhao HG, Aronovich EL, Whitley CB (1998) Genotype-phenotype correspondence in Sanfilippo syndrome type B. Am J Hum Genet 62:53–63CrossRefPubMed Zhao HG, Aronovich EL, Whitley CB (1998) Genotype-phenotype correspondence in Sanfilippo syndrome type B. Am J Hum Genet 62:53–63CrossRefPubMed
Metadata
Title
Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype
Authors
Marlies J. Valstar
Hennie T. Bruggenwirth
Renske Olmer
Ron A. Wevers
Frans W. Verheijen
Ben J. Poorthuis
Dicky J. Halley
Frits A. Wijburg
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 6/2010
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-010-9199-y

Other articles of this Issue 6/2010

Journal of Inherited Metabolic Disease 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.